trial

Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine

NCTId NCT00401973
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 199 (actual)
Sponsored by Eli Lilly and Company
Primary completion 2008-09
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
199 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2006-11
Primary completion
2008-09
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
OlanzapineamantadineMetforminzonisamideWellness education

Sponsors

Eli Lilly and CompanyLead Sponsor

Investigators

1
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)Study Director

Sites

15 total
National City, United StatesCanton, United StatesJohnson City, United StatesMemphis, United StatesDeSoto, United StatesRio de Janeiro, BrazilSalvador, BrazilBeer Yaacov, IsraelMexico City, MexicoBayamón, Puerto RicoPonce, Puerto RicoSan Juan, Puerto Rico

Linked catalysts

1
Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain A — primary completion2008-09

Facts & assertions

4 sourced
Enrollment
199
Phase
PHASE3
Primary Completion Date
2008-09
Status
COMPLETED
relationships
The graph out of here
drug
Olanzapine
drug
amantadine
drug
Metformin
drug
zonisamide
drug
Wellness education
drug
lead_sponsor
Eli Lilly and Company
company
indication
Schizophrenia
indication
Schizophrenia
indication
Schizoaffective Disorders
indication
investigator
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)
person